Using Rhodamine 123 Accumulation in CD8+ Cells as a Surrogate Indicator to Study the P-Glycoprotein Modulating Effect of Cepharanthine Hydrochloride In Vivo

The purpose of this study was the use of rhodamine 123 (Rho123) accumulation in peripheral blood CD8+cells as a surrogate indicator to evaluate the modulating effect of P-glycoprotein (P-gp) inhibitors in the multidrug resistance (MDR) tumor-bearing mouse model. Rho123 was administered to mice, and the fluorescence level in CD8+ cells was measured. Cepharanthine hydrochloride (CH) and verapamil (VER), two P-gp inhibitors, were administered to mice 1 hour prior to Rho123 administration in vivo or added to peripheral blood 1 hour prior to Rho123 addition ex vivo. The tumor inhibition effect of 5-fluorouracil/adriamycin/cisplatin (FAP) protocol plus CH was also investigated. A concentration- or dose-response relationship was shown between the concentration and dose of CH and Rho123 accumulation or the antitumor activity. In conclusion, the measurement of Rho123 accumulation in CD8+ cells provides a surrogate assay for the screening of candidate P-gp inhibitors in preclinical trials, and CH is effective in modulating P-gp-mediated MDR in vivo.

[1]  P. Galle,et al.  Future perspectives in hepatocellular carcinoma. , 2010, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[2]  A. Tang,et al.  Green tea catechins augment the antitumor activity of doxorubicin in an in vivo mouse model for chemoresistant liver cancer. , 2010, International journal of oncology.

[3]  J. Molnár,et al.  In vitro and in vivo multidrug resistance reversal activity by a Betti-base derivative of tylosin , 2010, British Journal of Cancer.

[4]  R. Mumper,et al.  Nanomedicinal strategies to treat multidrug-resistant tumors: current progress. , 2010, Nanomedicine.

[5]  S. Jaganathan,et al.  Effect of Honey and Eugenol on Ehrlich Ascites and Solid Carcinoma , 2010, Journal of biomedicine & biotechnology.

[6]  R. Igari,et al.  [Binocular diplopia and ptosis due to snakebite (Agkistrodon blomhoffi "mamushi")--a case report]. , 2010, Brain and nerve = Shinkei kenkyu no shinpo.

[7]  A. Zhu,et al.  Systemic Treatment of Hepatocellular Carcinoma: Dawn of a New Era? , 2010, Annals of Surgical Oncology.

[8]  W. Xin.  Establishment of Hca multidrug resistance mouse model , 2010 .

[9]  H. Rosing,et al.  Absence of both cytochrome P450 3A and P-glycoprotein dramatically increases docetaxel oral bioavailability and risk of intestinal toxicity. , 2009, Cancer research.

[10]  T. Fojo,et al.  A Phase I Study of the P-Glycoprotein Antagonist Tariquidar in Combination with Vinorelbine , 2009, Clinical Cancer Research.

[11]  L. Torre-Bouscoulet,et al.  In vitro cytotoxicity of CD8+ T cells in multi‐drug‐resistant tuberculosis. A preliminary report , 2009, Respirology.

[12]  H. Eguchi,et al.  Myelotoxicity of preoperative chemoradiotherapy is a significant determinant of poor prognosis in patients with T4 esophageal cancer , 2009, Journal of surgical oncology.

[13]  H. Utsumi,et al.  P-glycoprotein function in peripheral T lymphocyte subsets of myasthenia gravis patients: clinical implications and influence of glucocorticoid administration. , 2009, International immunopharmacology.

[14]  Y. Kim,et al.  Decreased expression of KAI1/CD82 metastasis suppressor gene is associated with loss of heterozygosity in melanoma cell lines. , 2009, Oncology reports.

[15]  S. Benvenuti,et al.  P-Glycoprotein inhibitory activity of lipophilic constituents of Echinacea pallida roots in a human proximal tubular cell line. , 2008, Planta medica.

[16]  R. C. Valente,et al.  ABCB1 (P-glycoprotein) but not ABCC1 (MRP1) is downregulated in peripheral blood mononuclear cells of spontaneously hypertensive rats , 2008, Pflügers Archiv - European Journal of Physiology.

[17]  V. Rumjanek,et al.  Independent Regulation of ABCB1 and ABCC Activities in Thymocytes and Bone Marrow Mononuclear Cells during Aging , 2007, Scandinavian journal of immunology.

[18]  M. Mckenna,et al.  CD56 Is a Sensitive and Diagnostically Useful Immunohistochemical Marker of Ovarian Sex Cord-Stromal Tumors , 2007, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[19]  S. Furusawa,et al.  The effects of biscoclaurine alkaloid cepharanthine on mammalian cells: implications for cancer, shock, and inflammatory diseases. , 2007, Life sciences.

[20]  P. Zinzani,et al.  Phase I/II trial of a P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), given orally in combination with the CHOP regimen in patients with non-Hodgkin's lymphoma , 2007, Leukemia & lymphoma.

[21]  S. Nutt,et al.  Functional subsets of mouse natural killer cells , 2006, Immunological Reviews.

[22]  R. Pérez-Tomás,et al.  Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. , 2006, Current medicinal chemistry.

[23]  J. Calixto,et al.  In vivo and in vitro modulation of MDR molecules in murine thymocytes. , 2006, International immunopharmacology.

[24]  W. Xia,et al.  [Reversal of multidrug resistance in drug-resistant cell line EAC/ADR by cepharanthine hydrochloride and its mechanism]. , 2005, Yao xue xue bao = Acta pharmaceutica Sinica.

[25]  S. Steinberg,et al.  A Phase I/II Study of Infusional Vinblastine with the P-Glycoprotein Antagonist Valspodar (PSC 833) in Renal Cell Carcinoma , 2004, Clinical Cancer Research.

[26]  E. Crivellato,et al.  Toxicologic and pharmacokinetic study of low doses of verapamil combined with doxorubicin. , 2002, Life sciences.

[27]  P. Augustijns,et al.  Inhibitory effect of fruit extracts on P‐glycoproteinrelated efflux carriers: an in‐vitro screening , 2002, The Journal of pharmacy and pharmacology.

[28]  M. Nakagawa,et al.  Reversal of P‐Glycoprotein‐mediated Paclitaxel Resistance by New Synthetic Isoprenoids in Human Bladder Cancer Cell Line , 2002, Japanese journal of cancer research : Gann.

[29]  M. Caligiuri,et al.  Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. , 2002, Blood.

[30]  C. Slapak,et al.  Modulation by LY335979 of P-glycoprotein function in multidrug-resistant cell lines and human natural killer cells. , 2001, Biochemical pharmacology.

[31]  H. Mouri,et al.  Modulation of doxorubicin sensitivity by cyclosporine A in hepatocellular carcinoma cells and their doxorubicin‐resistant sublines , 2001, Journal of gastroenterology and hepatology.

[32]  P. Gros,et al.  Rhodamine 123 binds to multiple sites in the multidrug resistance protein (MRP1). , 2000, Biochemistry.

[33]  V. Rumjanek,et al.  The in vivo effect of the administration of resistance-modulating agents on rhodamine 123 distribution in mice thymus and lymph nodes. , 1999, Cancer letters.

[34]  K. Sugimoto,et al.  P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of P-glycoprotein function by cyclosporin A and its analogue, PSC833. , 1999, Blood.

[35]  J. Asaumi,et al.  Direct antitumor effect of cepharanthin and combined effect with adriamycin against Ehrlich ascites tumor in mice. , 1995, Anticancer research.

[36]  J. Roh,et al.  Combined use of tamoxifen, cyclosporin A, and verapamil for modulating multidrug resistance in human hepatocellular carcinoma cell lines. , 1993, Yonsei medical journal.

[37]  M. Seki,et al.  [The effects of Cepharanthin on the recovery of hematopoietic stem cells after X-ray irradiation]. , 1991, Gan to kagaku ryoho. Cancer & chemotherapy.

[38]  Susan Budavari,et al.  The Merck index : an encyclopedia of chemicals, drugs, and biologicals , 1983 .

[39]  Susan Budavari,et al.  The Merck index. An encyclopedia of chemicals and drugs. , 1976 .